Literature DB >> 12904575

Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload.

Satoshi Okumura1, Gen Takagi, Jun-ichi Kawabe, Guiping Yang, Ming-Chih Lee, Chull Hong, Jing Liu, Dorothy E Vatner, Junichi Sadoshima, Stephen F Vatner, Yoshihiro Ishikawa.   

Abstract

The sympathetic nervous system is designed to respond to stress. Adenylyl cyclase (AC) is the keystone of sympathetic transmission, yet its role in response to acute overload in the heart or in the pathogenesis of heart failure is controversial. We examined the effects of pressure overload, induced by thoracic aortic banding, in mice in which type 5 AC, a major cardiac AC isoform, was disrupted (AC5-/-). Left ventricular weight/tibial length ratio (LVW/TL) was not different between the WT and AC5-/- at baseline and increased progressively and similarly in both groups at 1 and 3 wk after aortic banding. However, LV ejection fraction (LVEF) fell in WT at 3 wk after banding (from 70 +/- 2.8 to 57 +/- 3.9%, P < 0.05), and this decrease was associated with LV dilatation, indicating incipient cardiac failure. In contrast, AC5-/- mice did not exhibit a fall in LVEF from 74 +/- 2.2%. The number of apoptotic myocytes was similar at baseline, but it increased roughly 4-fold in WT at both 1 and 3 wk after banding, and significantly less, P < 0.05, in AC5-/-. Importantly, the increase in apoptosis occurred before the decline in LVEF in WT. The protective mechanism seems to involve Bcl-2, which was up-regulated significantly more in AC5-/- mice with pressure overload. Our findings suggest that limiting type 5 AC plays a protective role in response to pressure overload and the development of heart failure, potentially through limiting the incidence of myocardial apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12904575      PMCID: PMC187910          DOI: 10.1073/pnas.1733772100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

Review 1.  beta-adrenergic receptor signaling: an acute compensatory adjustment-inappropriate for the chronic stress of heart failure? Insights from Gsalpha overexpression and other genetically engineered animal models.

Authors:  S F Vatner; D E Vatner; C J Homcy
Journal:  Circ Res       Date:  2000-03-17       Impact factor: 17.367

Review 2.  Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase.

Authors:  N Defer; M Best-Belpomme; J Hanoune
Journal:  Am J Physiol Renal Physiol       Date:  2000-09

3.  Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice.

Authors:  J D Bisognano; H D Weinberger; T J Bohlmeyer; A Pende; M V Raynolds; A Sastravaha; R Roden; K Asano; B C Blaxall; S C Wu; C Communal; K Singh; W Colucci; M R Bristow; D J Port
Journal:  J Mol Cell Cardiol       Date:  2000-05       Impact factor: 5.000

4.  p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes against beta -adrenergic receptor-stimulated apoptosis. Evidence for Gi-dependent activation.

Authors:  C Communal; W S Colucci; K Singh
Journal:  J Biol Chem       Date:  2000-06-23       Impact factor: 5.157

Review 5.  Beta-adrenergic receptor-G protein-adenylyl cyclase signal transduction in the failing heart.

Authors:  D E Vatner; K Asai; M Iwase; Y Ishikawa; R P Shannon; C J Homcy; S F Vatner
Journal:  Am J Cardiol       Date:  1999-06-17       Impact factor: 2.778

6.  Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level.

Authors:  S B Liggett; N M Tepe; J N Lorenz; A M Canning; T D Jantz; S Mitarai; A Yatani; G W Dorn
Journal:  Circulation       Date:  2000-04-11       Impact factor: 29.690

7.  Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(salpha) mouse.

Authors:  K Asai; G P Yang; Y J Geng; G Takagi; S Bishop; Y Ishikawa; R P Shannon; T E Wagner; D E Vatner; C J Homcy; S F Vatner
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

8.  Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte beta-adrenergic signalling.

Authors:  N M Tepe; J N Lorenz; A Yatani; R Dash; E G Kranias; G W Dorn; S B Liggett
Journal:  Biochemistry       Date:  1999-12-14       Impact factor: 3.162

9.  Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes.

Authors:  W Z Zhu; M Zheng; W J Koch; R J Lefkowitz; B K Kobilka; R P Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

10.  Enhanced cardiac function in transgenic mice expressing a Ca(2+)-stimulated adenylyl cyclase.

Authors:  L Lipskaia; N Defer; G Esposito; I Hajar; M C Garel; H A Rockman; J Hanoune
Journal:  Circ Res       Date:  2000-04-14       Impact factor: 17.367

View more
  95 in total

1.  Effects of cardiac overexpression of type 6 adenylyl cyclase affects on the response to chronic pressure overload.

Authors:  Aziz Guellich; Shumin Gao; Chull Hong; Lin Yan; Thomas E Wagner; Sunil K Dhar; Bijan Ghaleh; Luc Hittinger; Kosaku Iwatsubo; Yoshihiro Ishikawa; Stephen F Vatner; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-18       Impact factor: 4.733

2.  The A-kinase anchoring protein Yotiao facilitates complex formation between adenylyl cyclase type 9 and the IKs potassium channel in heart.

Authors:  Yong Li; Lei Chen; Robert S Kass; Carmen W Dessauer
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.157

3.  Cellular localisation of adenylyl cyclase: a post-genome perspective.

Authors:  Ferenc A Antoni; Ulrich K Wiegand; Jamie Black; James Simpson
Journal:  Neurochem Res       Date:  2006-02       Impact factor: 3.996

4.  A conformational transition in the adenylyl cyclase catalytic site yields different binding modes for ribosyl-modified and unmodified nucleotide inhibitors.

Authors:  Jenna L Wang; Jian-Xin Guo; Qi-Yuan Zhang; Jay J-Q Wu; Roland Seifert; Gerald H Lushington
Journal:  Bioorg Med Chem       Date:  2007-02-11       Impact factor: 3.641

5.  Stimulation of renin secretion by catecholamines is dependent on adenylyl cyclases 5 and 6.

Authors:  Fadi Aldehni; Tong Tang; Kirsten Madsen; Michael Plattner; Andrea Schreiber; Ulla G Friis; H Kirk Hammond; Pyung Lim Han; Frank Schweda
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

6.  Adenylyl cyclase 6 deletion reduces left ventricular hypertrophy, dilation, dysfunction, and fibrosis in pressure-overloaded female mice.

Authors:  Tong Tang; N Chin Lai; H Kirk Hammond; David M Roth; Yuan Yang; Tracy Guo; Mei Hua Gao
Journal:  J Am Coll Cardiol       Date:  2010-04-06       Impact factor: 24.094

7.  An adenylyl cyclase-mAKAPbeta signaling complex regulates cAMP levels in cardiac myocytes.

Authors:  Michael S Kapiloff; Leslie A Piggott; Rachna Sadana; Jinliang Li; Lorena A Heredia; Edward Henson; Riad Efendiev; Carmen W Dessauer
Journal:  J Biol Chem       Date:  2009-07-01       Impact factor: 5.157

Review 8.  Gene therapy in heart failure.

Authors:  Leif Erik Vinge; Philip W Raake; Walter J Koch
Journal:  Circ Res       Date:  2008-06-20       Impact factor: 17.367

9.  Overexpression of adenylyl cyclase type 5 (AC5) confers a proarrhythmic substrate to the heart.

Authors:  Zhenghang Zhao; Gopal J Babu; Hairuo Wen; Nadezhda Fefelova; Richard Gordan; Xiangzhen Sui; Lin Yan; Dorothy E Vatner; Stephen F Vatner; Lai-Hua Xie
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-12-05       Impact factor: 4.733

10.  Type 5 adenylyl cyclase increases oxidative stress by transcriptional regulation of manganese superoxide dismutase via the SIRT1/FoxO3a pathway.

Authors:  Lo Lai; Lin Yan; Shumin Gao; Che-Lin Hu; Hui Ge; Amy Davidow; Misun Park; Claudio Bravo; Kousaku Iwatsubo; Yoshihiro Ishikawa; Johan Auwerx; David A Sinclair; Stephen F Vatner; Dorothy E Vatner
Journal:  Circulation       Date:  2013-03-27       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.